/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer s disease and launched the first approved tr…
$216.04
$0.61 (-0.28%)
EOD Sep 1, 2026
15.74% operating margin is respectable but not wide. ROIC at 5.16%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 2.2%, essentially flat. Margins also contracted 4.0pp. This is a business that needs a catalyst.
Free cash flow declined 25% versus the prior year, cash generation momentum has weakened. Operating margin contracted 4.0pp YoY, cost discipline may be slipping.
23.2x earnings, 13.2x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9.94B
▲ +2.2% YoY
Net Income (TTM)
$1.37B
▼ -20.8% YoY
Op. Margin
16.33%
▼ -4.0pp YoY
ROIC
5.53%
▼ -1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$2.42B
▼ -24.7% YoY
Op. Cash Flow (TTM)
$2.59B
▼ -23.3% YoY
Net Debt
$2.28B
Cash & Equiv.
$4.28B
5Y CAGR: -6.0%
5Y CAGR: -11.6%
Continue Research
SourceComputed from the 10-Q filed 29 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 30 Jul 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 23.2 and a price-to-free-cash-flow of 13.2, Biogen (BIIB) trades around a two-stage DCF intrinsic value of about $267.58 per share, so at $216.04 the stock looks around fair value (23.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Biogen scores 49/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $267.58 per share for BIIB, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $200.68. At today's $216.04, that puts the stock about 23.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Biogen scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 16.3% operating margin and a 5.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BIIB currently trades around its estimated intrinsic value and scores 49/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.